Concepedia

Publication | Closed Access

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.

46

Citations

13

References

2012

Year

Roberto Gedaly, Paul Angulo, Changguo Chen, Kate Townsend Creasy, Brett T. Spear, Jonathan Hundley, Michael F. Daily, Malay B. Shah, B. Mark Evers
PubMed

Abstract

The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.

References

YearCitations

Page 1